Valentina Garibotto

List of Publications by Year
in descending order

223 papers	6,676 citations	76196 40 h-index	79541 73 g-index
260 all docs	260 docs citations	260 times ranked	8113 citing authors

#	Article	IF	Citations
1	The logopenic/phonological variant of primary progressive aphasia. Neurology, 2008, 71, 1227-1234.	1.5	602
2	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
3	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
4	Education and occupation as proxies for reserve in aMCI converters and AD. Neurology, 2008, 71, 1342-1349.	1.5	201
5	InÂvivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 47-52.	1.1	185
6	In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage, 2008, 42, 306-314.	2.1	178
7	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage: Clinical, 2014, 6, 445-454.	1.4	172
8	A European multicentre PET study of fibrillar amyloid in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	3.3	170
9	Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiology of Aging, 2006, 27, 24-31.	1.5	139
10	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	3.3	134
11	Evidence of White Matter Changes on Diffusion Tensor Imaging in Frontotemporal Dementia. Archives of Neurology, 2007, 64, 246.	4.9	123
12	Disorganization of anatomical connectivity in obsessive compulsive disorder: A multi-parameter diffusion tensor imaging study in a subpopulation of patients. Neurobiology of Disease, 2010, 37, 468-476.	2.1	103
13	Individual Detection of Patients with Parkinson Disease using Support Vector Machine Analysis of Diffusion Tensor Imaging Data: Initial Results. American Journal of Neuroradiology, 2012, 33, 2123-2128.	1.2	99
14	Yield of MRI, high-density electric source imaging (HD-ESI), SPECT and PET in epilepsy surgery candidates. Clinical Neurophysiology, 2016, 127, 150-155.	0.7	97
15	Clinical Applications of Hybrid PET/MRI in Neuroimaging. Clinical Nuclear Medicine, 2013, 38, e13-e18.	0.7	92
16	Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. NeuroImage: Clinical, 2017, 14, 734-740.	1.4	89
17	Brain Magnetic Resonance Imaging Structural Changes in a Pedigree of Asymptomatic Progranulin Mutation Carriers. Rejuvenation Research, 2008, 11, 585-595.	0.9	87
18	Gender differences in healthy aging and Alzheimer's Dementia: A ^{18}Fâ€FDGâ€PET study of brain and cognitive reserve. Human Brain Mapping, 2017, 38, 4212-4227.	1.9	87

#	ARTICLE	IF	CITATIONS
19	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	3.3	86
20	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	1.5	85
21	White Matter Changes in Corticobasal Degeneration Syndrome and Correlation With Limb Apraxia. Archives of Neurology, 2008, 65, 796-801.	4.9	83
22	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	3.3	82
23	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	1.5	67
24	Projection Space Implementation of Deep Learning–Guided Low-Dose Brain PET Imaging Improves Performance over Implementation in Image Space. Journal of Nuclear Medicine, 2020, 61, 1388-1396.	2.8	66
25	Subcortical and deep cortical atrophy in Frontotemporal Lobar Degeneration. Neurobiology of Aging, 2011, 32, 875-884.	1.5	63
26	In vivo evidence for $GABA_A$ receptor changes in the sensorimotor system in primary dystonia. Movement Disorders, 2011, 26, 852-857.	2.2	61
27	A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1487-1491.	3.3	56
28	Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 57-69.	1.1	54
29	Does whole-body Patlak 18F-FDG PET imaging improve lesion detectability in clinical oncology?. European Radiology, 2019, 29, 4812-4821.	2.3	54
30	Deep learning–guided joint attenuation and scatter correction in multitracer neuroimaging studies. Human Brain Mapping, 2020, 41, 3667-3679.	1.9	52
31	Revisiting Brain Reserve Hypothesis in Frontotemporal Dementia: Evidence from a Brain Perfusion Study. Dementia and Geriatric Cognitive Disorders, 2009, 28, 130-135.	0.7	51
32	Education and occupation provide reserve in both ApoE ε4 carrier and noncarrier patients with probable Alzheimer's disease. Neurological Sciences, 2012, 33, 1037-1042.	0.9	51
33	In Vivo TSPO Signal and Neuroinflammation in Alzheimer's Disease. Cells, 2020, 9, 1941.	1.8	51
34	Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup. BioMed Research International, 2017, 2017, 1-8.	0.9	50
35	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	2.8	47
36	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. Neurology, 2007, 68, 875-876.	1.5	46

#	Article	IF	Citations
37	First imaging results of an intraindividual comparison of 11C-acetate and 18F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 68-78.	3.3	46
38	Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging. European Radiology, 2016, 26, 2297-2307.	2.3	45
39	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 353-357.	3.3	44
40	The predictive value of hypometabolism in focal epilepsy: a prospective study in surgical candidates. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1806-1816.	3.3	44
41	Cholinergic activity correlates with reserve proxies in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2694.e13-2694.e18.	1.5	43
42	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	2.2	42
43	[11C]-MP4A PET Cholinergic Measurements in Amnestic Mild Cognitive Impairment, Probable Alzheimer's Disease, and Dementia with Lewy Bodies: A Bayesian Method and Voxel-Based Analysis. Journal of Alzheimer's Disease, 2012, 31, 387-399.	1.2	41
44	Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses. NeuroImage: Clinical, 2016, 12, 234-240.	1.4	41
45	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	3.3	41
46	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 112-125.	0.7	40
47	Scan without evidence of dopaminergic deficit: A 10-year retrospective study. Parkinsonism and Related Disorders, 2016, 31, 53-58.	1.1	38
48	Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1642-1651.	3.3	38
49	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.4	37
50	All-in-one interictal presurgical imaging in patients with epilepsy: single-session EEG/PET/(f)MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1133-1143.	3.3	35
51	Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. Journal of Neurology, 2019, 266, 1771-1781.	1.8	35
52	Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. Journal of Neurology, 2005, 252, 1359-1362.	1.8	34
53	Quantification of amyloid PET for future clinical use: a state-of-the-art review. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3508-3528.	3.3	34
54	Regions of Interest-Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia. Clinical Nuclear Medicine, 2013, 38, e112-e117.	0.7	33

#	Article	IF	Citations
55	Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions. Molecular Imaging and Biology, 2016, 18, 302-312.	1.3	33
56	Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study. Journal of the Neurological Sciences, 2018, 385, 17-21.	0.3	33
57	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33
58	Localization of the epileptogenic tuber with electric source imaging in patients with tuberous sclerosis. Epilepsy Research, 2014, 108, 267-279.	0.8	30
59	Association of Adenosine Receptor Gene Polymorphisms and In Vivo Adenosine A1 Receptor Binding in The Human Brain. Neuropsychopharmacology, 2014, 39, 2989-2999.	2.8	29
60	Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome?. Parkinsonism and Related Disorders, 2016, 30, 62-66.	1.1	29
61	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. Alzheimer's Research and Therapy, 2021, 13, 187.	3.0	29
62	Neuroimaging of dementia in 2013: what radiologists need to know. European Radiology, 2013, 23, 3393-3404.	2.3	27
63	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	3.6	27
64	Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia With Lewy Bodies. Clinical Nuclear Medicine, 2017, 42, e96-e102.	0.7	26
65	Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images. Frontiers in Aging Neuroscience, 2017, 9, 146.	1.7	25
66	First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9. EJNMMI Research, 2018, 8, 108.	1.1	25
67	A voxel-based PET study of dopamine transporters in Parkinson's disease: Relevance of age at onset. Neurobiology of Disease, 2008, 31, 102-109.	2.1	24
68	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	3.3	23
69	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	3.3	23
70	PET evidence of central GABAergic changes in stiff-person syndrome. Movement Disorders, 2007, 22, 1030-1033.	2.2	22
71	Dual-phase amyloid PET: hitting two birds with one stone. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1300-1303.	3.3	22
72	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22

#	Article	IF	Citations
73	Beyond cognitive reserve: Behavioural reserve hypothesis in Frontotemporal Dementia. Behavioural Brain Research, 2013, 245, 58-62.	1.2	21
74	Assessment of Lesion Detectability in Dynamic Whole-Body PET Imaging Using Compartmental and Patlak Parametric Mapping. Clinical Nuclear Medicine, 2020, 45, e221-e231.	0.7	21
75	Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?. Journal of Alzheimer's Disease, 2020, 74, 411-419.	1.2	21
76	Nature versus Nurture in Frontotemporal Lobar Degeneration: the Interaction of Genetic Background and Education on Brain Damage. Dementia and Geriatric Cognitive Disorders, 2012, 33, 372-378.	0.7	20
77	Tracking the source of cerebellar epilepsy: Hemifacial seizures associated with cerebellar cortical dysplasia. Epilepsy Research, 2013, 105, 245-249.	0.8	19
78	Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging. Molecular Imaging and Biology, 2017, 19, 772-778.	1.3	19
79	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	3.3	19
80	Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model. Neurobiology of Aging, 2021, 103, 117-127.	1.5	19
81	Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 425-426.	0.9	18
82	90Y Time-of-flight PET/MR on a hybrid scanner following liver radioembolisation (SIRT). European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1744-1745.	3.3	18
83	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). NeuroImage: Clinical, 2019, 23, 101846.	1.4	18
84	COVID-19 and the brain: impact on nuclear medicine in neurology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2487-2492.	3.3	18
85	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	3.3	18
86	FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2012, 28, 941-950.	1.2	16
87	Gray Matter Densities in Limbic Areas and APOE4 Independently Predict Cognitive Decline in Normal Brain Aging. Frontiers in Aging Neuroscience, 2019, 11, 157.	1.7	16
88	Hybrid PET-MRI in Alzheimer's Disease Research. Methods in Molecular Biology, 2018, 1750, 185-200.	0.4	16
89	Low-Dose Radiation Therapy Reduces Amyloid Load in Young 3xTg-AD Mice. Journal of Alzheimer's Disease, 2022, 86, 641-653.	1.2	16
90	Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging. Frontiers in Oncology, 2016, 6, 73.	1.3	15

#	ARTICLE	IF	CITATIONS
91	Long-term Results of a Comparative PET/CT and PET/MRI Study of 11C-Acetate and 18F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e242-e246.	0.7	15
92	Basal forebrain metabolism in Alzheimer's disease continuum: relationship with education. Neurobiology of Aging, 2020, 87, 70-77.	1.5	15
93	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimer's Research and Therapy, 2021, 13, 105.	3.0	15
94	PET Imaging in Neurodegeneration and Neuro-oncology: Variants and Pitfalls. Seminars in Nuclear Medicine, 2021, 51, 408-418.	2.5	15
95	Reversible nonfluent aphasia and left frontal hypoperfusion during topiramate treatment. Epilepsy and Behavior, 2007, 10, 192-194.	0.9	14
96	18F-FDG PET/CT and Contrast-Enhanced CT in a One-Stop Diagnostic Procedure. Clinical Nuclear Medicine, 2012, 37, 453-459.	0.7	14
97	Molecular neuroimaging with PET/MRI. Clinical and Translational Imaging, 2013, 1, 53-63.	1.1	14
98	Spinal Uptake Mimicking Metastasis in SPECT/CT Bone Scan in a Patient With Superior Vena Cava Obstruction. Clinical Nuclear Medicine, 2013, 38, 908-909.	0.7	14
99	123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian From Cerebellar Variant of Multiple System Atrophy. Clinical Nuclear Medicine, 2018, 43, e33-e36.	0.7	14
100	Dopaminergic imaging separates normal pressure hydrocephalus from its mimics. Journal of Neurology, 2018, 265, 2434-2441.	1.8	14
101	Nicotinic receptor abnormalities as a biomarker in idiopathic generalized epilepsy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 385-395.	3.3	14
102	[Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 349-374.	1.0	14
103	Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis. Alzheimer Disease and Associated Disorders, 2010, 24, 108-114.	0.6	13
104	Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI. Medical Oncology, 2019, 36, 67.	1.2	13
105	Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson's disease – the PPMI cohort. BMC Neurology, 2020, 20, 192.	0.8	13
106	FDG PET/MR Imaging in Major Neurocognitive Disorders. Current Alzheimer Research, 2017, 14, 186-197.	0.7	13
107	Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns. Child's Nervous System, 2013, 29, 509-512.	0.6	12
108	Qualitative and Quantitative Evaluation of Blob-Based Time-of-Flight PET Image Reconstruction in Hybrid Brain PET/MR Imaging. Molecular Imaging and Biology, 2015, 17, 704-713.	1.3	12

#	Article	IF	Citations
109	The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1210-1218.	0.4	12
110	Localizing non-epileptiform abnormal brain function in children using high density EEG: Electric Source Imaging of focal slowing. Epilepsy Research, 2020, 159, 106245.	0.8	12
111	PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update. Current Vascular Pharmacology, 2015, 13, 209-217.	0.8	12
112	Persistent Autobiographical Amnesia: A Case Report. Behavioural Neurology, 2007, 18, 13-17.	1.1	11
113	Changes in brain glucose metabolism in subthalamic nucleus deep brain stimulation for advanced parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 770-774.	1.1	11
114	Morphological and Advanced Imaging of Epilepsy: Beyond the Basics. Children, 2019, 6, 43.	0.6	11
115	Less agreeable, better preserved? A PET amyloid and MRI study in a community-based cohort. Neurobiology of Aging, 2020, 89, 24-31.	1.5	11
116	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	3.3	11
117	Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. Diagnostics, 2022, 12, 1665.	1.3	11
118	The behavioural features of fatal familial insomnia: A new Italian case with pathological verification. Sleep Medicine, 2009, 10, 581-585.	0.8	10
119	Subcortical and Deep Cortical Atrophy in Frontotemporal Dementia due to Granulin Mutations. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 95-102.	0.6	10
120	Continuous bed motion Vs. step-and-shoot acquisition on clinical whole-body dynamic and parametric PET imaging. , 2015, , .		10
121	Parkinsonism Differentiates Idiopathic Normal Pressure Hydrocephalus from Its Mimics. Journal of Alzheimer's Disease, 2016, 54, 123-127.	1.2	10
122	Hippocampal Volume Loss, Brain Amyloid Accumulation, and APOE Status in Cognitively Intact Elderly Subjects. Neurodegenerative Diseases, 2019, 19, 139-147.	0.8	10
123	Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. Parkinsonism and Related Disorders, 2020, 78, 38-43.	1.1	10
124	Microbleeds and Medial Temporal Atrophy Determine Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study. Journal of Alzheimer's Disease, 2020, 77, 1431-1442.	1.2	10
125	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. Journal of Neurochemistry, 2023, 164, 346-363.	2.1	10
126	Adenosine A1 receptors in human brain and transfected CHO cells: Inhibition of [3H]CPFPX binding by adenosine and caffeine. Neuroscience Letters, 2011, 487, 415-420.	1.0	9

#	Article	IF	Citations
127	Hybrid PET/MRI as a tool to detect brown adipose tissue: Proof of principle. Obesity Research and Clinical Practice, 2015, 9, 613-617.	0.8	9
128	Amyloid Load, Hippocampal Volume Loss, and Diffusion Tensor Imaging Changes in Early Phases of Brain Aging. Frontiers in Neuroscience, 2019, 13, 1228.	1.4	9
129	Determinants of mesial temporal lobe volume loss in older individuals with preserved cognition: a longitudinal PET amyloid study. Neurobiology of Aging, 2020, 87, 108-114.	1.5	9
130	Radiologic Patterns of Necrosis After Proton Therapy of Skull Base Tumors. Canadian Journal of Neurological Sciences, 2013, 40, 800-806.	0.3	8
131	Re: Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimerâ€™s Disease (AD). Radiotherapy and Oncology, 2016, 118, 577-578.	0.3	8
132	Distinct spatiotemporal patterns for disease duration and stage in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 509-516.	3.3	8
133	PET amyloid in normal aging: direct comparison of visual and automatic processing methods. Scientific Reports, 2020, 10, 16665.	1.6	8
134	PET/CT-Based Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy: Impact on Treatment Management and Future Directions. Frontiers in Oncology, 2021, 11, 742093.	1.3	8
135	Alzheimerâ€™s Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus: Linking Functional Connectivity and Clinical Outcome. Journal of Alzheimer's Disease, 2021, 83, 1-12.	1.2	8
136	PET Radiotracers for Molecular Imaging in Dementia. Current Radiopharmaceuticals, 2014, 6, 215-230.	0.3	8
137	The role of molecular imaging in assessing degenerative parkinsonism â€" an updated review. Swiss Medical Weekly, 2018, 148, w14621.	0.8	8
138	A PET-MRI Case of Corticocerebellar Diaschisis After Stroke. Clinical Nuclear Medicine, 2011, 36, 821-825.	0.7	7
139	Peripheral Nerves, Tumors, and Hybrid PET-MRI. Clinical Nuclear Medicine, 2013, 38, e40-e42.	0.7	7
140	Feeling of presence in dementia with Lewy bodies is related to reduced left frontoparietal metabolism. Brain Imaging and Behavior, 2020, 14, 1199-1207.	1.1	7
141	Nicotinic Acetylcholine Receptor Density in the â€œHigher-Orderâ€•Thalamus Projecting to the Prefrontal Cortex in Humans: a PET Study. Molecular Imaging and Biology, 2020, 22, 417-424.	1.3	7
142	2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1090-1091.	3.3	7
143	Lifelong bilingualism and mechanisms of neuroprotection inÂ Alzheimer dementia. Human Brain Mapping, 2022, 43, 581-592.	1.9	7
144	Positron emission tomography changes in PARK1 mutation. Movement Disorders, 2006, 21, 127-130.	2.2	6

#	Article	IF	Citations
145	Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. Journal of the Neurological Sciences, 2015, 351, 127-132.	0.3	6
146	CO2BOLD assessment of moyamoya syndrome: Validation with single photon emission computed tomography and positron emission tomography imaging. World Journal of Radiology, 2016, 8, 887.	0.5	6
147	Higher availability of α4β2 nicotinic receptors (nAChRs) in dorsal ACC is linked to more efficient interference control. NeuroImage, 2020, 214, 116729.	2.1	6
148	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3033-3036.	3.3	6
149	Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 159-168.	1.0	6
150	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	1.1	6
151	Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.4	6
152	Highlights of the 32th Annual Congress of the EANM, Barcelona 2019: the nucleolympic games of nuclear medicine—a global competition for excellence. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1808-1819.	3.3	5
153	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European‐DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.4	5
154	Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2067-2069.	3.3	5
155	Finding our way through the labyrinth of dementia biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2320-2324.	3.3	5
156	Personality Impact on Alzheimer's Disease — Signature and Vascular Imaging Markers: A PET-MRI Study. Journal of Alzheimer's Disease, 2022, 85, 1807-1817.	1.2	5
157	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2106-2112.	3.3	5
158	Hybrid whole-body dynamic TOF PET imaging for simultaneous estimation of compartmental and patlak parametric maps from continuous bed motion data. , 2016, , .		4
159	Consolidation of a Learned Skill Correlates with Dopamine SPECT Uptake in Early Parkinson's Disease.		

#	ARTICLE	IF	CITATIONS
163	PET Imaging of Dopamine Neurotransmission During EEG Neurofeedback. Frontiers in Physiology, 2020, 11, 590503.	1.3	4
164	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	0.7	4
165	Personality Factors' Impact on the Structural Integrity of Mentalizing Network in Old Age: A Combined PET-MRI Study. Frontiers in Psychiatry, 2020, 11, 552037.	1.3	4
166	Neuroimaging of the Vulnerable Plaque. Current Vascular Pharmacology, 2015, 13, 182-191.	0.8	3
167	Severe early basal ganglia hypometabolism in neurodegeneration with brain iron accumulation. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1741-1742.	3.3	3
168	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. Clinical and Translational Imaging, 2018, 6, 471-482.	1.1	3
169	Higher nicotinic receptor availability in the cingulo‐insular network is associated with lower cardiac parasympathetic tone. Journal of Comparative Neurology, 2019, 527, 3014-3022.	0.9	3
170	The biomarker roadmap for the validation for Alzheimer's biomarkers: Methodological update for biomarkers of tauopathy. Alzheimer's and Dementia, 2020, 16, e039063.	0.4	3
171	Alzheimer's disease biomarker roadmap 2020: Time for tau. Alzheimer's and Dementia, 2020, 16, e039549.	0.4	3
172	A kinetics-based approach to amyloid PET semi-quantification. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2175-2185.	3.3	3
173	Significance of 18F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2015, 54, 211-216.	0.3	3
174	Determinants of Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study in a Community-based Cohort. Current Alzheimer Research, 2021, 18, 482-491.	0.7	3
175	Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer's Disease and Neurodegeneration: Old Drugs, New Concerns. Frontiers in Oncology, 2021, 11, 734881.	1.3	3
176	FDG PET–CT in detection of diaphragmatic metastasis of dedifferentiated liposarcoma: A case report. European Journal of Radiology Extra, 2011, 77, e35-e38.	0.1	2
177	Applications cliniques de l'imagerie hybride TEP-IRM. Medecine Nucleaire, 2012, 36, 605-614.	0.2	2
178	Teaching Neuro <i>Images</i> : Drug-induced parkinsonism with asymmetrical putaminal DaT binding. Neurology, 2015, 84, e159.	1.5	2
179	Joint Optimization of Kinetic Modelling and CBM Acquisition Parameters in Hybrid Whole-Body Dynamic PET Imaging. , 2017, , .		2
180	Neuroimaging in Movement Disorders. , 2018, , 1-36.		2

#	Article	IF	Citations
181	Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. Alzheimer's and Dementia, 2020, 16, e039557.	0.4	2
182	Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. NeuroImage: Clinical, 2021, 32, 102791.	1.4	2
183	Clinical Characterization of Atypical Primary Progressive Aphasia in a 3-Year Longitudinal Study: A Case Report. Cognitive and Behavioral Neurology, 2021, 34, 233-244.	0.5	2
184	Appropriate use criteria for dementia amyloid imaging in Switzerland – mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics. Nuklearmedizin - NuclearMedicine, 2021, 60, 7-9.	0.3	2
185	SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease. Neurobiology of Aging, 2022, 113, 73-83.	1.5	2
186	The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging. Journal of Alzheimer's Disease, 2022, , 1-8.	1.2	2
187	Corrigendum to "In‑vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease" [Parkinsonism Relat Disord 19 (2013) 47–52]. Parkinsonism and Related Disorders, 2013, 19, 921.	1.1	1
188	No more SWEDDs. Movement Disorders, 2016, 31, 1426-1426.	2.2	1
189	The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al.. Neurological Sciences, 2017, 38, 1883-1884.	0.9	1
190	Patient-Specific Hybrid Whole-body PET Parametric Imaging From SpeedModulated Continuous Bed Motion Dynamic Data. , 2017, , .		1
191	PET/MRI in Brain Tumors. , 2018, , 185-222.		1
192	PET/MRI in Breast Cancer. , 2018, , 261-280.		1
193	Imaging pattern and histological features of Gorham-Stout Disease of the radius. Journal of Solid Tumors, 2018, 8, 20.	0.1	1
194	Combined 123I-FP-CIT SPECT semiquantitative and visual assessment in parkinsonian syndromes and dementia with Lewy bodies – response to Kawada et al.. Journal of the Neurological Sciences, 2018, 392, 126-127.	0.3	1
195	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
196	Alzheimer's disease biomarker roadmap 2020: Second‑generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556.	0.4	1
197	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. Alzheimer's and Dementia, 2020, 16, e042628.	0.4	1
198	Imaging dopamine system transporter activity and connectivity in Alzheimer's dementia. Alzheimer's and Dementia, 2020, 16, e043304.	0.4	1

#	Article	IF	Citations
199	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort. Alzheimer's and Dementia, 2020, 16, e045436.	0.4	1
200	Proven validity and management impact of amyloid imaging in Alzheimerâ€™s diseaseâ€"repetita juvant. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1787-1790.	3.3	1
201	Edge Tracking of subjective contours in Biomedical Imaging. , 2007, , .		0
202	TEP/IRM hybride en neuro-imagerie. Medecine Nucleaire, 2013, 37, 561-566.	0.2	0
203	Editorial (Thematic Issue: Is Ischemic Stroke an Inflammatory Disease?). Current Vascular Pharmacology, 2015, 13, 144-145.	0.8	0
204	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
205	[P4â€"109]: EFFECT OF COGNITIVE RESERVE ON TAU BURDEN IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1299.	0.4	0
206	[P4â€"491]: THE AMYPADâ€DX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET. Alzheimer's and Dementia, 2017, 13, P1523.	0.4	0
207	ICâ€Pâ€007: VISUAL RATING SCALES IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT CHARACTERIZED FOR AMYLOIDOSIS. Alzheimer's and Dementia, 2018, 14, P18.	0.4	0
208	P2â€370: AMYLOIDâ€PET FOR MYELIN IMAGING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P836.	0.4	0
209	Quality Assurance of Small Animal Irradiation: Validation of a 3D-Printed Phantom for â€œQuasi In-Vivoâ€ Dosimetry. International Journal of Radiation Oncology Biology Physics, 2018, 102, e476.	0.4	0
210	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2018, , 1-26.		0
211	Neuroimaging in Movement Disorders. , 2019, , 1327-1361.		0
212	18F-FDG PET in Epilepsy. , 2019, , 65-76.		0
213	Clinical assessment of lesion detectability in dynamic whole-body PET imaging using compartmental and Patlak parametric mapping. , 2019, , .		0
214	Alzheimerâ€™s disease biomarker roadmap 2020: [18 F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550.	0.4	0
215	Inâ€vivo imaging of locus coeruleus integrity at ultraâ€high field: A feasibility study. Alzheimer's and Dementia, 2020, 16, e040835.	0.4	0
216	Extrastriatal dopaminergic and serotonergic pathways in Alzheimerâ€™s disease: A 123 Iâ€FPâ€CIT study. Alzheimer's and Dementia, 2020, 16, e041317.	0.4	0

#	Article	IF	Citations
217	Low‑dose radiation therapy: A new potential treatment targeting amyloid load and neuroinflammation in an AD rat model. Alzheimer's and Dementia, 2020, 16, e042402.	0.4	0
218	Prediction of Subtle Cognitive Decline in Normal Aging: Added Value of Quantitative MRI and PET Imaging. Frontiers in Aging Neuroscience, 2021, 13, 664224.	1.7	0
219	Incidental ¹⁸F-FDG Uptake of the Pubic Ramus and Abdominal Muscles due to Athletic Pubalgia During Acute Prostatitis. Molecular Imaging and Radionuclide Therapy, 2018, 27, 133-135.	0.3	0
220	PET imaging in dementia. , 2021, , .		0
221	Case 15: Non-lesional Temporal Epilepsy. , 2022, , 77-81.		0
222	Towards fingerprinting and identifiability within the Alzheimer's continuum using resting‑state functional connectivity. Alzheimer's and Dementia, 2021, 17, .	0.4	0
223	Brain Imaging. , 2015, , .		0